ReviewFrontiers in immunology2026
Tumor-associated neutrophils in lung adenocarcinoma: from mechanisms to therapeutic targeting.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) is the predominant subtype of non-small cell lung cancer (NSCLC), characterized by a complex tumor microenvironment (TME) where tumor-associated neutrophils (TANs) exert dual functions-a concept now well-established in broader NSCLC and pan-cancer studies. Despite the advances in immune checkpoint inhibitors (ICIs), primary and acquired resistance remain major obstacles. This review comprehensively dissects the regulatory network of TANs in LUAD, including their recruitment via the CXCR1/CXCR2 axis, polarization towards anti-tumorigenic N1 or pro-tumorigenic N2 phenotypes under the influence of TGF-β and IFN-γ, and the formation of neutrophil extracellular traps (NETs). We highlight the dual functions of TANs and NETs in both tumor promotion (immunosuppression, angiogenesis, metastasis) and tumor suppression (direct cytotoxicity, antigen presentation). Furthermore, we evaluate current therapeutic strategies targeting TANs, such as CXCR1/2 inhibitors (SX-682, Navarixin), PAD4 inhibitors (Cl-amidine), NET-degrading enzymes (DNase I), TGF-β inhibitors (Galunisertib), and myeloid modulators, with a focus on LUAD-specific preclinical and clinical evidence. Major challenges, including off-target toxicity, infection risk, and the lack of predictive biomarkers, are discussed. By bridging mechanistic insights with translational opportunities, this review provides a framework for developing neutrophil-targeted combination therapies to overcome immunotherapy resistance in LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.